Ectoine Composition to Reduce Age-Related Sirtuin Activity Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments fail to effectively counteract age-related loss of sirtuin activity, which is associated with various diseases and aging phenomena, particularly in the lungs and skin, and are not effective in treating idiopathic interstitial pneumonia or other diseases with unknown causes.

Innovation Solution

The use of ectoine, hydroxyectoine, and their salts, esters, and amides to enhance sirtuin activity, thereby improving cell differentiation and proliferation, particularly in lung and skin tissues, and treating diseases such as senile emphysema, idiopathic pulmonary fibrosis, and other age-related conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used, then general symptoms may be addressed, but age-related loss of sirtuin activity cannot be effectively counteracted

Engineering Contradiction:

Improveeffectiveness in counteracting sirtuin activity lossVSAvoidapplicability to various diseases and aging phenomena

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of known compounds (ectoine and hydroxyectoine) to create derivatives with enhanced sirtuin activating properties. By systematically varying molecular parameters such as substituent groups at positions 2, 5, and 6 of the tetrahydropyrimidine ring, the invention optimizes sirtuin activation while maintaining cellular compatibility and reducing side effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses sirtuin activators as intermediary substances that mediate between the administered compound and the sirtuin enzymes. These activators serve as molecular intermediaries that bind to sirtuins and enhance their deacetylase activity, thereby indirectly influencing gene expression, cell differentiation, and aging processes without directly modifying the sirtuin structure.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If sirtuin activators are administered, then sirtuin activity is enhanced, but the complexity of identifying effective compounds for specific diseases increases

Engineering Contradiction:

Improvesirtuin activity enhancementVSAvoididentification of disease-specific effective compounds

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent employs feedback mechanisms through in vitro and in vivo assays to evaluate sirtuin activation potency. By measuring deacetylase activity, gene expression changes, and cellular responses, the invention creates a feedback loop that guides the optimization of ectoine derivatives. This systematic evaluation provides quantitative data on sirtuin activation, enabling selection of compounds with desired potency and selectivity for specific disease indications.

Inventive Principle:

Principle #23Feedback

3Reliability

If ectoine and hydroxyectoine derivatives are used, then cell differentiation and proliferation are improved, but the risk of off-target effects may increase

Engineering Contradiction:

Improvecell differentiation and proliferation improvementVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing ectoine derivatives with specific substituent patterns that target particular sirtuin isoforms (SIRT1, SIRT2, SIRT3, etc.) or specific cellular compartments. By introducing different functional groups at positions 2, 5, and 6 of the tetrahydropyrimidine ring, the invention creates compounds with localized effects on specific sirtuin enzymes or tissue types, thereby enhancing therapeutic specificity and reducing off-target effects.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Ectoine and hydroxyectoine compositions significantly reduce sirtuin activity loss, effectively treating and preventing aging phenomena and diseases by enhancing sirtuin activity, improving cell differentiation and proliferation, and addressing conditions like senile emphysema and idiopathic pulmonary fibrosis.

Implementation Method 1

Ectoine and hydroxyectoine are capable of significantly reducing the loss of sirtuin activity

Methodology Applied

Scientific EffectChemical protection:

Data Source

PatentEP3426252B1Composition for stimulating sirtuin activity

Publication Date: 2025.07.02 BITOP AG

AI summary

The invention relates to a composition containing, as active substances, ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for stimulating sirtuin activity, in particular for the treatment of diseases associated with reduced sirtuin activity. This includes, in particular, different aging disorders and diseases which occur in particular in old age or are associated with disturbed cell differentiation or cell growth.